Pte Ltd. Bio Lexis Net Worth

What's Pte Lexis's mailing address?

Pte's mailing address filed with the SEC is 36 ROBINSON ROAD, #13-06 CITY HOUSE, P.O. BOX 142904, SINGAPORE, U0, 068877.

Insiders trading at Outlook Therapeutics Inc

Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over $1,453,842 worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth $33,411,235 . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S..., Ghiath M.Gms Ventures & Inv... a Ventures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of $11,985,869. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth $5,021,431.

What does Outlook Therapeutics Inc do?

overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t

Outlook Therapeutics Inc executives and stock owners

Outlook Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lawrence Kenyon,
  President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
• Lawrence A. Kenyon CPA,
  Exec. VP, CFO, Treasurer, Company Sec. & Director
• C. Russell Trenary III,
  Pres, CEO & Director
• Randy Thurman,
  Executive Chairman of the Board
• Terry Dagnon,
  Chief Operations Officer
• Jeffrey Evanson,
  Chief Commercial Officer
• Ralph H. Thurman,
  Independent Exec. Chairman
• Jeremy Feffer,
  IR Contact Officer
• Faisal Sukhtian,
  Independent Director
• Kurt Hilzinger,
  Independent Director
• Yezan Haddadin,
  Independent Director
• Andong Huang,
  Director
• Julian Gangolli,
  Director
• Gerd Auffarth,
  Director
• Jeff Evanson,
  Chief Commercial Officer
• Terry Dagnon,
  Chief Operating Officer
• Alicia Tozier,
  Sr. VP, Marketing & Market Access
• Joel Prieve,
  Sr. VP of Commercial Operations
• Elizabeth A. Yamashita,
  Advisor
• Dr. Balu N. Balasubramanian,
  Advisor
• Rick Gregory,
  Director of Marketing & Communications
• C Russell Iii Trenary,
  CEO AND PRESIDENT
• Pte Ltd.Pillai Arun Kumar S...,
  
• Ghiath M.Gms Ventures & Inv...,
  
• Joe Thomas,
  Director
• Pte Ltd. Bio Lexis,
  10% owner
• Faisal Ghiath Gms Ventures ...,
  
• Arun Kumar Pillai,
  Director
• Ventures Llc Syntone,
  
• Julia A Haller,